Skip to main content

Advertisement

SpringerLink
Log in

Guidelines for Glomerulonephritis

Their Importance in Diagnosis and Designing a Management Strategy

  • Practical Disease Management
  • Published:
Disease Management and Health Outcomes

Abstract

There is a wide variety of disorders which affect the glomeruli, the basic filtering units of the kidney. Clinical diagnosis of specific glomerular diseases is difficult because the same glomerular disease can manifest in different ways and different glomerular disease can produce the same clinical manifestations. Several findings are common to many glomerular diseases. They include the findings of dysmorphic erythrocytes in the urinary sediment and the presence of large amounts of albuminuria. Renal function may be increased, normal or decreased. The various combination of these signs give rise to a number of distinct clinical syndromes, namely, asymptomatic proteinuria or haematuria, nephrotic syndrome, acute glomerulonephritis, rapidly progressive glomerulonephritis and chronic glomerulonephritis.

Renal biopsy is often required for a definitive diagnosis. Clinical features, such as severe or prolonged nephrosis, renal insufficiency or hypertension predict a high likelihood of progression to end-stage renal disease. The treatment of glomerulonephritis will depend on the aetiology and the clinical presentation. It may be considered in 2 broad categories: the specific treatment for the renal injury and the management of pathophysiological consequences of glomerular disease, such as fluid retention, hypertension, hyperkalaemia and uraemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jacobs C, Sciwood NH. Renal replacement therapy for endstage renal failure in France: current status and evolutive trends over the last decade. Am J Kidney Dis 1995; Jan 25: 188–95

    Article  PubMed  CAS  Google Scholar 

  2. Glassock RJ, Cohen AH. The primary glomerulopathies. Dis Mon 1996; 42: 329–83

    Article  PubMed  CAS  Google Scholar 

  3. Tiebosch A, Wolters J, Frederik P, et al. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int 1987; 32: 112–6

    Article  PubMed  CAS  Google Scholar 

  4. Raine AEG. Epidemiology, development and treatment of endstage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. Diabetologia 1993; 36: 1199–204

    Article  Google Scholar 

  5. Schena FP, Gesualdo L, Grandaliano G, et al. Progression of renal damage in human glomerulonephritides: is there sleight of hand in winning the game? Kidney Int 1997; 52: 1439–57

    Article  PubMed  CAS  Google Scholar 

  6. Baud L. The emerging role of mediators in glomerulonephritis. Presse Med 1998; 27: 69–71

    PubMed  CAS  Google Scholar 

  7. Ritz E, Keller C, Bergis KH. Nephropathy of type II diabetes mellitus. Nephral Dial Transplant 1996; 11 Suppl. 9: 38–44

    Article  Google Scholar 

  8. Bellotti V, Merlini G. Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant 1996; 11 Suppl. 9: 53–62

    Article  PubMed  Google Scholar 

  9. Knebelmann B, Breillat C, Forestier L. et al. Spectrum of mutations in the COL4A5 gene in X-linked Alport syndrome. Am J Hum Genet 1996; 59: 1221–32

    PubMed  CAS  Google Scholar 

  10. Schmid M, Meyer S, Wegner R, et al. Increased genetic risk of hypertension in glomerulonephritis? J Hypertens 1990; Jun 8: 573–7

    Article  PubMed  CAS  Google Scholar 

  11. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. N Engl J Med 1989; 320: 1161–5

    Article  PubMed  CAS  Google Scholar 

  12. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pirna Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 438–43

    Article  PubMed  CAS  Google Scholar 

  13. Freedman BI, Ober KP, Tuttle AB, et al. Familial clustering of end-stage renal disease in African-Americans with non-insulin-dependent diabetes mellitus. J Am Soc Nephrol 1995; 25: 710–3

    CAS  Google Scholar 

  14. Rambausek M, Hartz G, Waldherr R, et al. Familial glomerulonephritis. Pediatr Nephrol 1987; 1: 416–8

    Article  PubMed  CAS  Google Scholar 

  15. Conlon PJ, Butterly D, Albers F, et al. Clinical and pathological features of familial focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 26: 34–40

    CAS  Google Scholar 

  16. Goodman DJ, Clarke B, Hope RN, et al. Familial focal glomerulosclerosis: a genetic linkage to the HLA locus? Am J Nephrol 1995; 15: 442–5

    Article  PubMed  CAS  Google Scholar 

  17. Levy M. Multiplex families in IgA nephropathy. Contrib Nephrol 1993; 104: 46–53

    PubMed  CAS  Google Scholar 

  18. Sato K, Oguchi H, Hora K, et al. Idiopathic membranous nephropathy in two brothers. Nephron 1987; 46: 174–8

    Article  PubMed  CAS  Google Scholar 

  19. Levy M, Halbwachs-Mecarelli L, Gubler MC, et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; Dec 30: 949–56

    Article  PubMed  CAS  Google Scholar 

  20. Jensen JE, Nielsen SH, Foged L, et al. The Micral test for diabetic microalbuminuria: predictive values as a function of prevalence. Scand J Clin Lab Invest 1996; 56: 117–22

    Article  PubMed  CAS  Google Scholar 

  21. Roth S, Renner E, Rathert P. Microscopic hematuria: advances in identification of glomerular dysmorphic erythrocytes. J Urol 1991; 146: 680–4

    PubMed  CAS  Google Scholar 

  22. Schulster VL, Seldin DW. Renal clearance In: Scidin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. New York: Raven Press, 1985: 365

    Google Scholar 

  23. Dondi M, Fanti S. Determination of individual renal function through noninvasive methodologies. Curr Opin Nephrol Hypertens 1995; 4: 520–4

    Article  PubMed  CAS  Google Scholar 

  24. Cockcroft DW, Gault MH. Prediction of Creatinine clearance from serum Creatinine. Nephron 1976; 16: 31–6

    Article  PubMed  CAS  Google Scholar 

  25. McPherson RA. Serologic evaluation of renal status. Clin Lab Med 1993; 13: 69–87

    PubMed  CAS  Google Scholar 

  26. D’Amico G, Sinico RA, Ferrario F. Renal vasculitis. Nephrol Dial Transplant 1996; 11, Suppl. 9: 69–74

    Article  PubMed  Google Scholar 

  27. Mogensen CE, Hansen KW, Sommer S, et al. Microalbuminuria: studies in diabetes, essential hypertension and renal diseases as compared with a background population. Adv Nephrol 1991; 20: 191–228

    CAS  Google Scholar 

  28. Jerums G, Panagiotopoulos S, Tsalamandris C, et al. Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int 1997; 52, Suppl. 63: S87–S92

    Google Scholar 

  29. Grimm RH, Svendsen KH, Kasiske B, et al. Proteinuria is a risk factor for mortality over 10 years of follow-up. Kidney Int 1997; 52, Suppl. 63: S10–4

    Google Scholar 

  30. Philippi PJ, Reynolds J, Yamauchi H, et al. Persistent proteinuria in asymptomatic individuals: renal biopsy study of 50 patients. Mil Med 1966; 131: 1311–7

    Google Scholar 

  31. King SE. Diastolic hypertension and chronic proteinuria. Am J Cardiol 1962; 9: 669–74

    Article  PubMed  CAS  Google Scholar 

  32. King SE. Albuminuria (Proteinuria) in renal disease: II: preliminary observations on the clinical course of patients with orthostatic albuminuria. NY State J Med 1959; 59: 825–32

    CAS  Google Scholar 

  33. Ruggenenti P, Perna A, Mosconi L, et al. On behalf of the ‘gruppo italiano di studi epidemiologico in nefrologia’ (GISEN) Urinary protein excretion rate is the best independent predictor of ESFR in non-diabetic Proteinuric chronic nephropathies. Kidney Int 1998; 53: 1209–16

    Article  PubMed  CAS  Google Scholar 

  34. Modification of diet in renal disease study group. The modification of diet in renal disease study; design, methods, and results from the feasibility study. Am J Kidney Dis 1992, 20: 18–33

    Google Scholar 

  35. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 1995; 25: 103–6

    Article  PubMed  CAS  Google Scholar 

  36. Zeller K, Whittacker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78–84

    Article  PubMed  CAS  Google Scholar 

  37. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injurt in the pathogenesis of progressive glomerular sclerosis. N Engl J Med 1982, 307: 652–9

    Article  PubMed  CAS  Google Scholar 

  38. El Nahas AM. Mechanisms of progression and consequences of nephron reduction. In: Cameron S, Davison AM, Grunfeld JP, et al. Oxford Textbook of Nephrology, Oxford: Oxford University Press, 1992: 1191–227

    Google Scholar 

  39. Pichler R, Giachelli C, Young B, et al. The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Miner Electrolyte Metab 1995, 21: 317–27

    PubMed  CAS  Google Scholar 

  40. Oda T, Hotta O, Taguma Y, et al. Clinicopathological significance of intratubular giant macrophages in progressive glomerulonephritis. Kidney Int 1998; 53: 1190–200

    Article  PubMed  CAS  Google Scholar 

  41. Frimat L, Hestin D, Aymard B, et al. IgAnephropathy in patients over 50 years of age: a multicentre, prospective study. Nephral Dial Transplant 1996; 11: 1043–7

    Article  CAS  Google Scholar 

  42. Béné MC, Hurault de Ligny B, Kessler M, et al. Tonsils in IgA nephropathy. Contrib Nephrol 1993; 104: 153–61

    PubMed  Google Scholar 

  43. Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histological analysis. J Am Soc Nephrol 1996; 7: 543–9

    PubMed  CAS  Google Scholar 

  44. Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53: 1111–7

    Article  PubMed  CAS  Google Scholar 

  45. Davison AM, Lambie AT. Salt-poor albumin in the management of nephrotic syndrome. BMJ 1974; 1: 481

    Article  PubMed  CAS  Google Scholar 

  46. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, et al. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998 Jul; 161: 430–9

    PubMed  CAS  Google Scholar 

  47. Maschio G, Alberti D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45

    Article  PubMed  CAS  Google Scholar 

  48. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effects of plood pressure-lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963–74

    PubMed  CAS  Google Scholar 

  49. Van Essen GG, Rensma PL, de Zeeuw D. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 94–5

    Article  PubMed  Google Scholar 

  50. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37–46

    Article  PubMed  CAS  Google Scholar 

  51. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus Captopril in patients over 65 with heart failure. Lancet 1997; 349: 747–52

    Article  PubMed  CAS  Google Scholar 

  52. Lafayette RA, Mayer G, Park SK. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766–71

    Article  PubMed  CAS  Google Scholar 

  53. Noda M, Fukuda R, Matsuo T, et al. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997; 52 Suppl. 63: S136–S9

    Google Scholar 

  54. Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 1997; 52 Suppl 63: S111–S4

    Google Scholar 

  55. Zoja C, Abbate M, Corna D, et al. Pharmacologie control of angiotensin II ameliorates renal disease while reducing renal TGF-b in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 1998; 31: 453–63

    Article  PubMed  CAS  Google Scholar 

  56. Klore HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with Proteinurie renal diseases: risks or benefits of calcium channel blockers. Kidney Int 1998; 53: 1559–73

    Article  Google Scholar 

  57. Rodicio JL, Campo C, Ruilope LM. Renal effects of calcium channel blockers: what they can and what they can’t do. Nephrol Dial Transplant 1997; 12: 25–8

    Article  Google Scholar 

  58. Kasiske BL, Lakatua JDA, Ma JZ, et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998, 31: 954–61

    Article  PubMed  CAS  Google Scholar 

  59. Ikizler A, Greene J, Wingard R, et al. Spontaneous dietary protein intake during progression of chronic renal failure. J Am J Soc Nephrol 1995; 6: 1386–91

    CAS  Google Scholar 

  60. Luvarghi F, Fantuzzi AL, Medici G, et al. Natural history of nutrition in chronic renal failure. Nephrol Dial Transplant 1996; 11 Suppl.: 75–84

    Article  Google Scholar 

  61. Ordonez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638–42

    Article  PubMed  CAS  Google Scholar 

  62. Massy ZA, Ma JZ, Louis TA, et al. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188–98

    Article  PubMed  CAS  Google Scholar 

  63. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommandations to the scientific advisory board of the National Kidney Foundation from an ad hoc commitee of the council on diabetes mellitus of the national kidney foundation. Am J Kidney Dis 1995; 25: 107–12

    Article  PubMed  CAS  Google Scholar 

  64. Orthe SR, Ritz E, Schrier RW. Renal risks of smoking. Kidney Int 1997; 51: 1669–77

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Néphrologie, Hôpital de Brabois, Centre Hospitalo-Universitaire de Nancy, Rue du Morvan, 54500, Vandoeuvre-les-Nancy, France

    Edith Renoult, Luc Frimat & Michele Kessler

Authors
  1. Edith Renoult
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luc Frimat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Kessler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Renoult, E., Frimat, L. & Kessler, M. Guidelines for Glomerulonephritis. Dis-Manage-Health-Outcomes 6, 213–224 (1999). https://doi.org/10.2165/00115677-199906040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-199906040-00004

Keywords

Search

Navigation